Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by International Medical Center of Japan.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Ministry of Health, Labour and Welfare, Japan
Information provided by:
International Medical Center of Japan
ClinicalTrials.gov Identifier:
NCT00544128
First received: October 12, 2007
Last updated: February 6, 2009
Last verified: February 2009
  Purpose

A non-inferiority randomized control trial in treatment naïve HIV patients to compare virologic effect of two backbone regimens with Epzicom (lamivudine and abacavir) and Truvada (emtricitabine and tenofovir). Both arms are treated with fixed combination of ritonavir boosted atazanavir as key drugs.


Condition Intervention Phase
HIV Infections
Drug: lamivudine, abacavir , ritonavir, atazanavir
Drug: emtricitabine, tenofovir, ritonavir, atazanavir
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Multicenter Study Comparing the Safety and Efficacy of Once Daily Regimen Containing Epzicom or Truvada Combined With Ritonavir Boosted Atazanavir as Initial Therapy for HIV-1 Infection (ET Study)

Resource links provided by NLM:


Further study details as provided by International Medical Center of Japan:

Primary Outcome Measures:
  • antiretroviral effect over 48 weeks [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The immunologic effects from baseline at the 48th and 144th week [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
  • Reasons of treatment failure by 144th week [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
  • Adverse events and their rate of incidence by 144th week [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 240
Study Start Date: October 2007
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Epzicom Arm
Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
Drug: lamivudine, abacavir , ritonavir, atazanavir
Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
Active Comparator: Truvada Arm
Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg
Drug: emtricitabine, tenofovir, ritonavir, atazanavir
Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.

Detailed Description:

In treatment naïve HIV-1-infected patients, once daily combination antiretroviral therapy containing ritonavir boosted atazanavir combined with Epzicom will offer non inferior antiretroviral efficacy compared to ritonavir boosted atazanavir combined with Truvada. This non inferiority hypothesis is studied by a randomized, open label, multicenter trial over 48 weeks as the primary endpoint and long term safety of both arms are followed for 144 weeks.

The primary endpoint is the antiretroviral effect over 48 weeks.

The secondary endpoints are;

  1. The immunologic effects from baseline at the 48th and 144th week
  2. Reasons of treatment failure by 144th week
  3. Adverse events and their rate of incidence by 144th week
  4. Serum concentration of tenofovir in selected patients
  5. Serum concentration of atazanavir in selected patients
  6. Renal complication in tenofovir arm
  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of HIV infection,
  • Antiretroviral initiation is recommended by current clinical guidelines,
  • Treatment naïve,
  • Age over 20 years old Japanese,
  • Able to obtain written informed consent

Exclusion Criteria:

  • Current malabsorption condition,
  • Prior use of lamivudine for hepatitis B treatment,
  • Positive serology of Hepatitis B surface antigen,
  • Patients who have following abnormal laboratory results within 6 weeks prior enrollment;

    1. alanine aminotransferase is more than 2.5 times higher of upper normal limit
    2. estimated glomerular filtration rate is less than 60ml/min by Cockcroft-Gault equation
    3. serum phosphate level is less than 2.0mg/dl
  • Patients with hemophilia, diabetes mellitus which require pharmacological treatment, congestive heart failure, cardiomyopathy or other serious medical condition
  • Patients in pregnancy or breat feeding
  • Patients who are taking medications contraindicated combine use of study medicine
  • Patients whose primary care physicians consider inadequate to be enroll the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00544128

Contacts
Contact: Shinichi Oka, MD +81-3-5273-5193 oka@imcj.hosp.go.jp
Contact: Miwako Honda, MD +81-3-3202-7181 ext 5639 mihonda@imcj.acc.go.jp

Locations
Japan
International Medical Center of Japan Recruiting
Shinjuku, Tokyo, Japan, 1628655
Contact: Shinichi Oka, MD    +81-3-5273-5193    oka@imcj.hosp.go.jp   
Contact: Miwako Honda, MD    +81-3-3202-7181 ext 5639    mihonda@imcj.acc.go.jp   
Sponsors and Collaborators
International Medical Center of Japan
Ministry of Health, Labour and Welfare, Japan
Investigators
Study Chair: Shinichi Oka, MD International Medical Center of Japan
  More Information

No publications provided

Responsible Party: Shinichi Oka, Director general, AIDS Clinical Center, International Medical Center of Japan
ClinicalTrials.gov Identifier: NCT00544128     History of Changes
Other Study ID Numbers: IMCJ-H19-466, ET001
Study First Received: October 12, 2007
Last Updated: February 6, 2009
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by International Medical Center of Japan:
HIV
initial therapy
once daily
randomized trial
non inferiority
Treatment Naive

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Lamivudine
Tenofovir
Tenofovir disoproxil
Abacavir
Ritonavir
Atazanavir
Emtricitabine
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents
HIV Protease Inhibitors
Protease Inhibitors

ClinicalTrials.gov processed this record on July 31, 2014